PDT Partners’s Keros Therapeutics KROS Stock Holding History

PDT Partners’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$122K	Sell	11,405 -21,339	-65%	-$238K	0.01%	480
2026 Q1	$361K	Sell	32,744 -79,439	-71%	-$1.23M	0.02%	448
2025 Q4	$2.28M	Sell	112,183 -220,632	-66%	-$3.87M	0.15%	228
2025 Q3	$5.27M	Hold	332,815	–	–	0.33%	94
2025 Q2	$4.44M	Buy	332,815 +56,755	+21%	+$766K	0.25%	136
2025 Q1	$2.81M	Buy	+276,060	New	+$3.21M	0.2%	178
2023 Q2	–	Sell	-22,657	Closed	-$967K	–	619
2023 Q1	$967K	Buy	22,657 +56	+0.2%	+$2.83K	0.13%	270
2022 Q4	$1.09M	Sell	22,601 -62	-0.3%	-$2.9K	0.18%	201
2022 Q3	$853K	Sell	22,663 -24,883	-52%	-$862K	0.13%	267
2022 Q2	$1.31M	Buy	47,546 +30,391	+177%	+$1.33M	0.12%	299
2022 Q1	$933K	Buy	+17,155	New	+$881K	0.08%	401
2021 Q2	–	Sell	-3,876	Closed	-$239K	–	893
2021 Q1	$239K	Buy	+3,876	New	+$246K	0.02%	664

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

PDT Partners's KROS Position: Q2 2026 in Review

PDT Partners reduced its Keros Therapeutics (KROS) stake by 65% in Q2 2026, selling an estimated $238K and leaving 11,405 shares worth $122K. The position accounts for 0.01% of the portfolio, ranked #480.

PDT Partners first reported a position in KROS in Q1 2021 and has held it in 12 quarters since. The position peaked at $5.27M in Q3 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

PDT Partners held 11,405 shares of Keros Therapeutics worth $122K as of Q2 2026.
PDT Partners sold 21,339 Keros Therapeutics shares in Q2 2026, an estimated $238K.
Keros Therapeutics made up 0.01% of PDT Partners's portfolio in Q2 2026, its #480 holding.
PDT Partners first reported a position in Keros Therapeutics in Q1 2021 and has held it in 12 quarters since.
PDT Partners's Keros Therapeutics position peaked at $5.27M in Q3 2025.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.